Ignite Creation Date:
2024-05-06 @ 11:39 AM
Last Modification Date:
2024-10-26 @ 12:48 PM
Study NCT ID:
NCT03564197
Status:
RECRUITING
Last Update Posted:
2023-10-18
First Post:
2018-04-11
Brief Title:
18F-PD-L1 PETCT in Nivolumab Treated Patients With NSCLC
Sponsor:
The Netherlands Cancer Institute
Organization:
The Netherlands Cancer Institute
Study Overview
Official Title:
18F-PD-L1 PETCT to Predict Response to Nivolumab in Patients With NSCLC
Status:
RECRUITING
Status Verified Date:
2023-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A multicenter single arm biomarker exploration and validation study Eighty patients with NSCLC that are eligible for first line chemo-immunotherapy first line nivolumabipilimumab or 2nd line and beyond PD-L1 immunotherapy monotherapy according to EMA label and national guidelines will be enrolled in this trial All subjects will undergo a whole body 18F-PD-L1 PETCT scan before start of nivolumab containing treatment Patients will continue treatment until disease progression withdrawal of patient consent or unacceptable toxicity
Detailed Description:
18F-PD-L1 PETCT scan to predict durable reponse to nivolumab containing treatment in patients with NSCLC
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| CA209-9XC | OTHER | Bristol-Myers Squibb | None |